Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

por Niu, Zhi-Yun, Sun, Li, Wen, Shu-Peng, Song, Zheng-Rong, Xing, Lina, Wang, Ying, Li, Jian-Qiang, Zhang, Xue-Jun, Wang, Fu-Xu
Publicado 2021